BioClavis has announced the planned creation of 43 new jobs with a £10.5 million investment supported by Scottish Enterprise.
Bioclavis is a new spin-out from Californian molecular profiling company Biospyder, to be based at the Clinical Innovation Zone at Glasgow’s Queen Elizabeth University Hospital, creating 43 new jobs.
BioSpyder’s investment has been supported by a £4.5m Seek & Solve research and development grant from Scottish Enterprise. It forms part of a total investment of £10.5m, which will see BioClavis adapt BioSpyder’s TempO-Seq platform technology into a novel diagnostic tool for precision medicine in a number of high value clinical indications, in close collaboration with the health service and university researchers.
Joel McComb, CEO of BioSpyder and BioClavis said: “We’re very excited to build on the success we’ve had in other molecular profiling applications and bring this novel method to bear on discovery and deployment of next generation genomic diagnostics.
“We determined Glasgow, Scotland to be the ideal location for this initiative based in large part on the support and close working relationships with Scottish Enterprise, NHS and the University.”
NextGate, a global leader in healthcare enterprise identification, announced the opening of a new office in Glasgow, Scotland to...Read More
Scotland is to have its own £15.8 million artificial intelligence health research centre, which promises to enable better patient...Read More
Councillor Susan Aitken, Leader of Glasgow City Council, was today (7 November) joined by pupils from Garnetbank Primary to...Read More
Sign-up to our email updates for the latest investment opportunities and information in Glasgow. Fill out the form below with your email.
